Glycosmedia Weekly Diabetes News - 02/05/2021

Residual β cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia

β Cell function can persist in long-duration T1DM. With a peak C-peptide concentration of >0.03 nmol/L, we observed clinically meaningful reductions in the prevalence of severe hypoglycemia (Journal of Clinical Investigation)

Acute glycaemic management before, during and after exercise for cardiac rehabilitation participants with diabetes mellitus

A joint statement of the British and Canadian Associations of Cardiovascular Prevention and Rehabilitation, the International Council for Cardiovascular Prevention and Rehabilitation and the British Association of Sport and Exercise Sciences (British Journal of Sports Medicine)

Use of Dipeptidyl Peptidase‐4 inhibitors and prognosis of COVID‐19 in hospitalized patients with type 2 diabetes: a propensity score analysis from the CORONADO study

These data support the safety of DPP‐4 inhibitors for diabetes management during the COVID‐19 pandemic and they should not be discontinued (Diabetes, Obesity and Metabolism)

GLP‐1 RA and atrial fibrillation in the cardiovascular outcome trials

This commentary suggests that the use of GLP‐1 RAs was not associated with an increased risk for incident atrial fibrillation reported as serious adverse event in individuals with type 2 diabetes who either have increased cardiovascular risk or established cardiovascular disease when compared to placebo (Diabetes/Metabolism Research and Reviews)

Micro-controlled thermal stimulator for detecting fine fiber changes in patients with diabetes mellitus: a diagnostic accuracy study

MTS is an accurate, sensitive, and specific instrument for the evaluation of diabetic neuropathy as compared with the tuning fork as the standard method and, consequently, it could be of help for the early diagnosis of diabetic neuropathy (Primary Care Diabetes)

Essential diabetes medicines and health outcomes in 127 countries

Listing of diabetes medicines on NEMLs has the potential to improve population health outcomes related to mortality in countries with diverse incomes and diabetes prevalence without necessarily increasing diabetes health expenditure (Diabetes, Obesity and Metabolism)

Glucosuric, renal and hemodynamic effects of a dual inhibitor of SGLT1 and SGLT2, licogliflozin, in patients with chronic kidney disease: a randomized trial

Licogliflozin treatment results in significantly increased UGE and favorable changes in urinary electrolytes and hemodynamics in patients with varying degrees of CKD (eGFR≥45 mL/min/1.73 m2) (Diabetes, Obesity and Metabolism)

Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year national population-based cohort study

Our data highlight persistent adverse pregnancy outcomes in women with type 1 or type 2 diabetes. Maternal glycaemia and BMI are the key modifiable risk factors. No maternity clinics were had appreciably better outcomes than any others, suggesting that health-care system changes are needed across all clinics (The Lancet Diabetes & Endocrinology)